Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells

Cancer Letters

Volumn 313, Issue 1, 2011, Pages 26-43

  Manavalan, Tissa T ^a   Teng, Yun ^a   Appana, Savitri N ^b   Datta, Susmita ^b   Kalbfleisch, Theodore S ^a   Li, Yong ^a   Klinge, Carolyn M ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Breast cancer; Endocrine resistance; MicroRNA; SERMs; Tamoxifen resistance

Indexed keywords

AFIMOXIFENE; MICRORNA; MICRORNA 10A; MICRORNA 125B; MICRORNA 181; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 21; MICRORNA 22; MICRORNA 222; MICRORNA 29A; MICRORNA 93; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN LY2; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA ISOLATION;

APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TAMOXIFEN; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 80054090363     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.018     Document Type: Article

References (84)

1. Peng J., Sengupta S., Jordan V.C. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med. Chem. 2009, 9:481-499.
2. Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 2004, 11:643-658.
3. Arpino G., Wiechmann L., Osborne C.K., Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 2008, 29:217-233.
4. Clarke R., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., Skaar T.C., Gomez B., O'Brien K., Wang Y., Hilakivi-Clarke L.A. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339.
5. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
6. Djuranovic S., Nahvi A., Green R. A parsimonious model for gene regulation by miRNAs. Science 2011, 331:550-553.
7. Nelson K.M., Weiss G.J. MicroRNAs and cancer: past, present, and potential future. Mol. Cancer Ther. 2008, 7:3655-3660.
8. Iorio M.V., Ferracin M., Liu C.-G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
9. Volinia S., Calin G.A., Liu C.-G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. 2006, 103:2257-2261.
10. Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., Liang S., Leminen A., Deng S., Smith L., Johnstone C.N., Chen X.-M., Liu C.-G., Huang Q., Katsaros D., Calin G.A., Weber B.L., Butzow R., Croce C.M., Coukos G., Zhang L. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008, 68:10307-10314.
11. Bhat-Nakshatri P., Wang G., Collins N.R., Thomson M.J., Geistlinger T.R., Carroll J.S., Brown M., Hammond S., Srour E.F., Liu Y., Nakshatri H. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucl. Acids Res. 2009, 37:4850-4861.
12. Maillot G., Lacroix-Triki M., Pierredon S., Gratadou L., Schmidt S., Benes V., Roche H., Dalenc F., Auboeuf D., Millevoi S., Vagner S. Widespread estrogen-dependent repression of microRNAs involved in breast tumor cell growth. Cancer Res. 2009, 69:8332-8340.
13. O'Day E., Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010, 12:201.
14. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., Iorio M.V., Visone R., Sever N.I., Fabbri M., Iuliano R., Palumbo T., Pichiorri F., Roldo C., Garzon R., Sevignani C., Rassenti L., Alder H., Volinia S., Liu C.-g., Kipps T.J., Negrini M., Croce C.M. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Eng. J. Med. 2005, 353:1793-1801.
15. Drakaki A., Iliopoulos D. MicroRNA gene networks in oncogenesis. Curr. Genom. 2009, 10:35-41.
16. Mocellin S., Pasquali S., Pilati P. Oncomirs: from tumor biology to molecularly targeted anticancer strategies. Mini Rev. Med. Chem. 2009, 9:70-80.
17. Verghese E.T., Hanby A.M., Speirs V., Hughes T.A. Small is beautiful: microRNAs and breast cancer-where are we now?. J. Pathol. 2008, 215:214-221.
18. Klinge C.M. Estrogen regulation of microRNA expression. Curr. Genom. 2009, 10:169-183.
19. Wickramasinghe N., Manavalan T., Dougherty S., Riggs K., Li Y., Klinge C. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucl. Acids Res. 2009, 37:2584-2595.
20. Castellano L., Giamas G., Jacob J., Coombes R.C., Lucchesi W., Thiruchelvam P., Barton G., Jiao L.R., Wait R., Waxman J., Hannon G.J., Stebbing J. The estrogen receptor-alpha induced microRNA signature regulates itself and its transcriptional response. Proc. Natl. Acad. Sci. 2009, 106:15732-15737.
21. Miller T.E., Ghoshal K., Ramaswamy B., Roy S., Datta J., Shapiro C.L., Jacob S., Majumder S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27(Kip1). J. Biol. Chem. 2008, 283:29897-29903.
22. Rao X., Di Leva G., Li M., Fang F., Devlin C., Hartman-Frey C., Burow M.E., Ivan M., Croce C.M., Nephew K.P. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30:1082-1097.
23. Xin F., Li M., Balch C., Thomson M., Fan M., Liu Y., Hammond S.M., Kim S., Nephew K.P. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 2009, 25:430-434.
24. Bronzert D.A., Greene G.L., Lippman M.E. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 1985, 117:1409-1417.
25. Mullick A., Chambon P. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res. 1990, 50:333-338.
26. Crawford A.C., Riggins R.B., Shajahan A.N., Zwart A., Clarke R. Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS ONE 2010, 5:e8604.
27. Frasor J., Chang E.C., Komm B., Lin C.-Y., Vega V.B., Liu E.T., Miller L.D., Smeds J., Bergh J., Katzenellenbogen B.S. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006, 66:7334-7340.
28. Riggs K.A., Wickramasinghe N.S., Cochrum R.K., Watts M.B., Klinge C.M. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Cancer Res. 2006, 66:10188-10198.
29. Brunner N., Boysen B., Jirus S., Skaar T.C., Holst-Hansen C., Lippman J., Frandsen T., Spang-Thomsen M., Fuqua S.A., Clarke R. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997, 57:3486-3493.
30. Smyth G.K., Speed T.P. Normalization of cDNA microarray data. Methods 2003, 31:265-273.
31. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. (Article3).
32. Shang Y., Hu X., DiRenzo J., Lazar M.A., Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103:843-852.
33. Kisanga E.R., Gjerde J., Guerrieri-Gonzaga A., Pigatto F., Pesci-Feltri A., Robertson C., Serrano D., Pelosi G., Decensi A., Lien E.A. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin. Cancer Res. 2004, 10:2336-2343.
34. Rao X., Di Leva G., Li M., Fang F., Devlin C., Hartman-Frey C., Burow M.E., Ivan M., Croce C.M., Nephew K.P. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2010.
35. Jiang J., Lee E.J., Gusev Y., Schmittgen T.D. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucl. Acids Res. 2005, 33:5394-5403.
36. Davoren P.A., McNeill R.E., Lowery A.J., Kerin M.J., Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol. Biol. 2008, 9:76.
37. Peltier H.J., Latham G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14:844-852.
38. Roush S., Slack F.J. The let-7 family of microRNAs. Trends Cell Biol. 2008, 18:505-516.
39. Boyerinas B., Park S.-M., Hau A., Murmann A.E., Peter M.E. The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 2010, 17:F19-36.
40. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70:7027-7030.
41. Sampson V.B., Rong N.H., Han J., Yang Q., Aris V., Soteropoulos P., Petrelli N.J., Dunn S.P., Krueger L.J. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in burkitt lymphoma cells. Cancer Res. 2007, 67:9762-9770.
42. Lan F.F., Wang H., Chen Y.C., Chan C.Y., Ng S.S., Li K., Xie D., He M.L., Lin M.C., Kung H.F. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16INK4A. Int. J. Cancer 2010, 128:319-331.
43. Dubik D., Dembinski T.C., Shiu R.P.C. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 1987, 47:6517-6521.
44. Zhao Y., Deng C., Wang J., Xiao J., Gatalica Z., Recker R.R., Xiao G.G. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 2011, 127:69-80.
45. Chen J.-Q., Russo J. ER[alpha]-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochim. Biophys. Acta (BBA) - Rev. Cancer 2009, 1796:162-175.
46. Di Leva G., Gasparini P., Piovan C., Ngankeu A., Garofalo M., Taccioli C., Iorio M.V., Li M., Volinia S., Alder H., Nakamura T., Nuovo G., Liu Y., Nephew K.P., Croce C.M. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J. Natl. Cancer Inst. 2010, 102:706-721.
47. Zhao J.-J., Lin J., Yang H., Kong W., He L., Ma X., Coppola D., Cheng J.Q. MicroRNA-221/222 negatively regulates ERalpha and associates with tamoxifen resistance in breast cancer. J. Biol. Chem. 2008, 283:31079-31086.
48. Wu H., Zhu S., Mo Y.Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009, 19:439-448.
49. Farazi T.A., Horlings H.M., ten Hoeve J.J., Mihailovic A., Halfwerk H., Morozov P., Brown M., Hafner M., Reyal F., van Kouwenhove M., Kreike B., Sie D., Hovestadt V., Wessels L.F.A., van de Vijver M.J., Tuschl T. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011, 71:4443-4453.
50. Wijayaratne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.M., McDonnell D.P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999, 140:5828-5840.
51. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14:1649-1660.
52. Prossnitz E.R., Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell. Endocrinol. 2009, 308:32-38.
53. Paroo Z., Ye X., Chen S., Liu Q. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 2009, 139:112-122.
54. Huang H., Xie C., Sun X., Ritchie R.P., Zhang J., Chen Y.E. MiR-10a contributes to retinoid acid-induced smooth muscle cell differentiation. J. Biol. Chem. 2010, 285:9383-9389.
55. Ørom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 2008, 30:460-471.
56. Davidson N.E., Bronzert D.A., Chambon P., Gelmann E.P., Lippman M.E. Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. Cancer Res. 1986, 46:1904-1908.
57. Mattie M.D., Benz C.C., Bowers J., Sensinger K., Wong L., Scott G.K., Fedele V., Ginzinger D., Getts R., Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 2006, 5:24.
58. Thomas P., Pang Y., Filardo E.J., Dong J. Identity of an estrogen membrane receptor coupled to a G Protein in human breast cancer cells. Endocrinology 2005, 146:624-632.
59. Kang L., Zhang X., Xie Y., Tu Y., Wang D., Liu Z., Wang Z.-Y. Involvement of estrogen receptor variant ER-{alpha}36, Not GPR30, in nongenomic estrogen signaling. Mol. Endocrinol. 2010, 24:709-721.
60. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-[alpha] 36, a novel variant of human estrogen receptor-[alpha] 66. Biochem. Biophys. Res. Commun. 2005, 336:1023-1027.
61. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. PNAS 2006, 103:9063-9068.
62. Lee L.M.J., Cao J., Deng H., Chen P., Z Gatalica, Wang Z.-Y. ERalpha36, a Novel Variant of ERalpha, is Expressed in ER-positive and -negative Human Breast Carcinomas. Anticancer Res. 2008, 28:479-483.
63. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 2001, 276:35684-35692.
64. Frasor J., Stossi F., Danes J.M., Komm B., Lyttle C.R., Katzenellenbogen B.S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004, 64:1522-1533.
65. Uhlmann S., Zhang J.D., Schwager A., Mannsperger H., Riazalhosseini Y., Burmester S., Ward A., Korf U., Wiemann S., Sahin O. MiR-200bc/429 cluster targets PLC[gamma] 1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 2010, 29:4297-4306.
66. Lim K.B., Ng C.Y., Ong C.K., Ong C.S., Tran E., Nguyen T.T., Chan G.M., Huynh H. Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780. Breast Cancer Res. Treat. 2001, 68:127-138.
67. El Etreby M.F., Liang Y., Wrenn R.W., Schoenlein P.V. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 1998, 51:149-168.
68. Economopoulos K., Sergentanis T. Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 2010, 122:545-551.
69. Brockdorff B.L., Skouv J., Reiter B.E., Lykkesfeldt A.E. Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines. Int. J. Cancer 2000, 88:902-906.
70. Sindhu R.K., Koo J.R., Sindhu K.K., Ehdaie A., Farmand F., Roberts C.K. Differential regulation of hepatic cytochrome P450 monooxygenases in streptozotocin-induced diabetic rats. Free Radic. Res. 2006, 40:921-928.
71. Spink D.C., Spink B.C., Cao J.Q., DePasquale J.A., Pentecost B.T., Fasco M.J., Li Y., Sutter T.R. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 1998, 19:291-298.
72. Tsuchiya Y., Nakajima M., Kyo S., Kanaya T., Inoue M., Yokoi T. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res. 2004, 64:3119-3125.
73. Hamburger A.W. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J. Mammary Gland Biol. Neoplasia 2008, 13:225-233.
74. Liu B., Ordonez-Ercan D., Fan Z., Edgerton S.M., Yang X., Thor A.D. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int. J. Cancer 2007, 120:1874-1882.
75. Scott G.K., Goga A., Bhaumik D., Berger C.E., Sullivan C.S., Benz C.C. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 2007, 282:1479-1486.
76. Revillion F., Pawlowski V., Lhotellier V., Louchez M.M., Peyrat J.P. MRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen. Anticancer Res. 2003, 23:1455-1460.
77. Cochrane D.R., Howe E.N., Spoelstra N.S., Richer J.K. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J. Oncol. 2010, 2010:821717.
78. Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Therapeut. 2009, 8:1055-1066.
79. Hurteau G.J., Carlson J.A., Spivack S.D., Brock G.J. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67:7972-7976.
80. Bracken C.P., Gregory P.A., Kolesnikoff N., Bert A.G., Wang J., Shannon M.F., Goodall G.J. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008, 68:7846-7854.
81. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
82. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
83. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283:14910-14914.
84. Kirschmann D.A., Seftor E.A., Nieva D.R., Mariano E.A., Hendrix M.J. Differentially expressed genes associated with the metastatic phenotype in breast cancer. Breast Cancer Res. Treat. 1999, 55:127-136.